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1 
INTRODUCTION 
Lung cancer is one of the most common cancers in the world. Lung 
cancer accounts for 15 % of all newly diagnosed cancers worldwide and is the 
leading cause of cancer deaths.
[1]
 According to Madras Metropolitan Tumour 
Registry (MMTR), it is the most common cancer among males accounting for 
around 11% of all cancers .
[2] 
For treatment purpose lung cancer is divided broadly into 2 groups, 
small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). 
[3] 
Overall survival of  lung cancer is poor with 5 year overall survival for all 
stages of lung cancer put together is around  15 %.
[4]
 More than half of the 
lung cancer patients present in advanced stage and median survival of these 
patients is around 6- 8 months. 
Till early 21
st
 century, cisplatin based doublet chemotherapy was 
standard of care in  patients with metastatic carcinoma lung who are in good 
performance status, which produced objective response of 20-30% and median 
survival of 6-8 months.
[5] 
The real path breaking discovery in the management of advanced 
NSCLC came with the invention of epidermal growth factor receptors (EGFR) 
inhibitors, which changed the natural history of lung cancer especially in the 
subset of lung cancer with EGFR mutation. 
 
2 
IDEAL-1 and IDEAL-2 studies confirmed the effectiveness of EGFR 
inhibitors as second and third line chemotherapy in relapsed carcinoma lung 
with acceptable toxicity profile.
 [6, 7] 
 IPASS trial published in 2009  was 
conducted on patients from East Asia and around 60 % of patients were 
positive for EGFR mutation and these patients when treated with gefitinib had 
significant progression free survival (PFS) compared to those treated with 
chemotherapy.
 [8]
 Thus EGFR inhibitors have become the drug of choice in 
patients with advanced lung cancer who have positive EGFR mutation. 
The most common method used for the detection of EGFR mutation 
was through direct sequencing of DNA.
 [9]
 But due to low sensitivity presently 
this method is not preferred worldwide. The newer and more sensitive method 
for detecting EGFR mutation which is being used worldwide is RT- PCR 
using ARMS (amplified refractory mutation system) technique. The most 
important drawback of this method is the cost involved in EGFR mutation 
testing and because of which, this test is difficult to perform in countries with 
limited resources where the access to EGFR testing is limited.
 [10, 11]
   
Any surrogate tests which are cost effective and have high sensitivity 
and specificity to detect EGFR mutation is the need of the day .Various 
immunohistochemistry (IHC) markers have been tried as surrogate tests to 
detect EGFR mutation , some of the promising being P-AKT,P- EGFR and 
TTF-1. 
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There is a limited data regarding EGFR mutation status in Indian 
patients with lung cancer and their outcome after treatment with 
chemotherapy/TKI. In the study by Louis et al done at cancer institute 
between January 2009 to December 2010, where TKI was prescribed 
depending on factors like female sex, never smoker and poor performance 
status .In this study 1 year PFS was better in TKI arm compared to 
chemotherapy.
 [12] 
 
Present study is designed as continuation of the study by Louis et al, 
where in EGFR mutation testing is done in all patients of lung cancer and 
treatment is based on result of mutation analysis. Also this study is intended to  
find out the correlation between EGFR mutation detected through RT-PCT by 
using ARMS technique and P- AKT , TTF-1 done through IHC ,which can act 
as  surrogate tests in patients with metastatic carcinoma lung who requires 
EGFR mutation testing. 
One of the important factors to be considered in the treatment of 
metastatic lung cancer is improvement in quality of life. Present study also 
aims to compare quality of life between tyrosine kinase inhibitors and standard 
chemotherapeutic agents. 
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AIMS AND OBJETIVES 
 
PRIMARY AIMS 
 
 To find out correlation between EGFR mutation status with P-
AKT,TTF-1. 
 
 To find out the quality of life of patient on tyrosine kinase inhibitor and 
chemotherapy. 
 
SECONDARY AIMS 
 
 To find demographic profile of patients with adenocarcinoma of lung 
presenting at our hospital. 
 
 To find out the EGFR mutation status of these patients and response to 
treatment.  
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REVIEW OF LITERATURE 
Lung cancer or bronchogenic carcinoma mainly includes cancer 
originating from bronchi or lung parenchyma. Lung cancer accounts for 15% 
of all newly diagnosed cancer and is the most common cause of death 
worldwide and is responsible for 1.38 million deaths annually, as of 2008. 
[1]
 
In United States the death due to lung cancer is more than the combined death 
from prostate, colon and breast cancer.  
In south India lung cancer is the most common cause of death in males 
and 6
th
 most common cause of death among females. According to Madras 
Metropolitan Tumour Registry (MMTR),lung cancer is the most common 
cancer in males accounting for 10.9% of  all cancer among males and seventh 
most common cancer among females accounting for 3.3%  of all cancers in 
females.
[2]
 
Majority of the lung cancer are seen in patients above the age of 60 
years and 30 % of lung cancer are seen in patient above 70 year.  
The 4 major sub types of lung cancer include   
Adenocarcinoma 
Squamous cell carcinoma 
Large cell carcinoma  
Small cell carcinoma. 
[13]
 
Adenocarcinoma is the most common subtype of lung cancer followed 
by squamous cell carcinoma.
 [14]
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For treatment purpose lung cancer can be classified as small cell lung 
cancer (SCLC) and non small cell lung cancer(NSCLC) and NSCLC 
comprises of 85 % of all lung cancers.
[3]
 
The most common cause for lung cancer is smoking which accounts for          
80-90 %  of lung cancers. Around 90% of cancer death in males and 70 % of 
cancer deaths in females were attributed to smoking 
[15]
. Passive smoking 
which is inhalation of smoke from others smoking is also an etiological factor 
for lung cancer. Persons living with the smoke, in  the same house has 20-30 
% increased risk of  developing lung cancer and person working with the 
smoker, in the same smoking environment has 16-20 % increased risk of lung 
cancer.
[16]
 A recent meta-analysis  showed  the relative risk of developing lung 
cancer is 1.15 to 1.31  in never-smoking women due to passive smoking from 
spouses.
[17] 
Other etiological factors for lung cancer include exposure to asbestos , 
heavy metals like uranium, nickel chromate, beryllium and  radon gas.  
Previous exposure of radiation to lung also is a risk factor for developing lung 
cancer.  
Lung cancers are aggressive and metastasize via lymphatic and 
haematogenous routes to bone, brain, adrenal gland and liver if left untreated. 
Treatment of  Advanced Lung Cancer 
Treatment of lung cancer depends on histology, performance status and 
stage of the disease. Over all the prognosis of lung cancer is poor and 5 year 
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overall survival is around 15 % .The best survival seen after complete surgical 
resection of stage 1A NSCLC patient which is as high as 70 %. On the other 
hand survival of patient of SCLC, extensive disease is as less as < 1%.
 [4]
 
Over 80 % of all diagnosed case of lung cancer are of advanced stage, 
and will not be amenable for curative treatment. The aim of treatment in this 
set of patients is to improve the quality of life and to improve overall survival. 
As already stated the overall survival of metastatic carcinoma lung is 
dismal with median survival of 6-8 months. But with the advent of newer 
chemotherapeutic agents and targeted therapy median overall survival has 
improved in the last decade. Presently 1/3
rd
 of patients with stage 3B and 4 are 
alive at 1 year and 2 year overall survival is around 10-21%.
[18]
 
Two large randomized control trial conducted in 1970-80‟s clearly 
showed superiority of cisplatin containing combination chemotherapy over 
best supportive care (BSC). 
Canadian trial which composed of 150 patients, randomly assigned 
patients into cisplatin+vindesine or cisplatin+adriamycine+cyclophosphamide 
(CAP) or best supportive care. In these trial patients receiving cisplatin based 
chemotherapy had median survival of 33 weeks compared to 23 weeks of BSC 
group. 
[19]
 
Another large trial Big Lung Trial, 725 patients were randomly 
assigned to 3 cycles cisplatin based chemotherapy to BSC, confirmed 
chemotherapy improved survival by 8 months .
[5]
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With these trials cisplatin based doublet chemotherapy became standard 
of care in patients with advanced lung cancer in good performance status, 
which showed objective response of 20- 30% and median survival of 6- 8 
months.  
Updated meta-analysis of chemotherapy for advanced lung cancer in 
1995, which included 2714 patients enrolled in 16 randomized control trials 
showed significant benefit of chemotherapy compared to best supportive care 
with hazard ratio (HR) of 0.77 which is equivalent to absolute increase in 
survival of 9%, from 20% to 29%, and increase in median survival of 1.5 
months (from 4.5 months to 6 months favoring chemotherapy).
 [20]
 
One more meta-analysis in which cisplatin based chemotherapy was 
compared with carboplatin based chemotherapy, which included 2968 patients 
with advanced carcinoma lung, cisplatin based chemotherapy resulted in 
higher response rate  ( 30% v/s 24%) but overall survival and treatment related 
mortality was similar in cisplatin and carboplatin arms.
[21]
 
Recently published ASCO guidelines for chemotherapy in advanced 
lung cancer has clearly stated that good performance status is the most 
important prognostic factor, and only patients in good performance status can 
achieve prolonged survival and improvement in quality of life when started on 
chemotherapy. 
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EGFR Inhibitors in Advanced Lung Cancer 
The major progress in the treatment of lung cancer has come from the 
development of molecular targets, mainly with the invention of tyrosine kinase 
inhibitors which targets EGFR pathway. This is a result of the progress made 
in understanding the disease biology, signaling pathways involved in lung 
cancer. Treatment of metastatic lung cancer with TKI like erlotinib or gefitinib  
in patients who have EGFR mutation has significantly improved Progression 
free survival(PFS), overall survival (OS) and quality of life (QOL) 
Phase 1 studies in early 2000 have showed that TKI‟s are well tolerated 
and have tolerable side effects. IDEAL-1 trial (Irissa dose evaluation in early 
lung) tried gefitinib in second line setting, showed response rate of 18 %. 
IDEAL 2 trial which was conducted in USA, gefitinib was administered in 
patients who had earlier been exposed to cisplatin and docetaxol showed 
response rate of 11%.
 [6, 7]
 On the basis of above two trials, FDA approved 
gefitinib in treatment of metastatic adenocarcinoma in patients with platinum 
and docetaxel failure. The evidence for using gefitinib in upfront setting has 
come from IPASS trial in which patients were recruited from various countries 
of East Asia. 
[8]
 In this trial 1217 patients of advanced adenocarcinoma of lung 
who were never smoker (< 100 cigarettes in their lifetime) or former light 
smokers (stopped smoking > 15 years back and had history of smoking for < 
10 pack years) were randomly assigned to geftinib or paclitaxel and 
carboplatin in 1:1 ratio in upfront setting.    
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The primary objective was to show non inferiority of gefitinib to 
paclitaxel/carboplatin which was met in the trial. 1 year progression free 
period was 24.9 % and 6.7 % respectively for gefitinib and chemotherapy. 
Response rate was also significantly higher with gefitinib (43 % v/s 32.2%). 
EGFR mutation data was available for 437 patients, 261 patients (59.7%) were 
EGFR mutation positive. The PFS was significantly better in patients treated 
with gefitinib treated patients compared to chemotherapy treated patients who 
were EGFR positive with hazard ratio of 0.48.  In EGFR mutation negative 
patients PFS was better in patients treated with chemotherapy compared to 
patients receiving gefitinib. 
In OPTIMAL trial, which was conducted in China, 165 patients who 
were EGFR mutation positive were randomly assigned in 1:1 ratio to either 
erlotinib or gemcitabine and carboplatin. The median PFS was significantly 
longer in erlotinib arm compared to chemotherapy arm (13.4 months v/s 4.6 
months with hazard ratio of  o.16). The toxicity profile was also favoring 
erlotinib arm. 
[22]
 
In EURTAC trial, which was conducted in 42 hospitals from France, 
Italy and Spain, 174 patients who were EGFR mutation positive were 
randomized in 1:1 ratio to either erlotinib or chemotherapy(cisplatin  with 
gemcitabine or docetaxol). The median PFS of erlotinib arm was 9.7 months 
compared to 5.2 months  in chemotherapy arm with  hazard ratio of   0.37 .
[23]
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On the basis of above trials EGFR inhibitors have become the treatment 
of choice in patients who have EGFR mutation in first line setting. 
Quality of Life 
With small survival benefit with most chemotherapeutic agents with 
regards to overall survival, the focus in metastatic lung cancer should be on 
improvement in quality of life. Randomized trials have clearly demonstrated 
the improvement in quality of life, with chemotherapeutic agents compared to 
BSC.  
In a recently published North East Japan study group 002 trial, the 
quality of life was better in patients treated with gefitinib compared to 
chemotherapy and this was maintained for long time, indicating gefitinib was 
well tolerated compared to chemotherapeutic agents.
[24]
 
In  IPASS study Health-related quality of life was one of  secondary 
endpoints . In EGFR mutation positive, the geﬁtinib treatment was associated 
with a signiﬁcant improvement in global quality of life (total score reported at 
FACT-L) compared to chemotherapy.
[8]
 
EGFR Signaling Pathway 
Epidermal growth factor receptor (EGFR) is a transmembrane 
glycoprotein with extracellular ligand binding domain and intracellular 
domain having tyrosine kinase activity. On ligand binding the receptor 
dimerizes, which leads to activation of tyrosine kinase domain which instead 
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activates RAS/RAF/MAPK pathway and PI3K-Akt pathway which regulate 
cell proliferation, survival and transformation. 
The persistent activation of tyrosine kinase domain is believed to play 
role in neoplastic activity and hence EGFR activation is believed to play 
critical role in neoplastic process. [
25, 26] 
 
 
 
EGFR is found over expressing in many tumors including lung cancer, 
head and neck cancer, pancreatic cancer, carcinoma gall bladder and so forth. 
In lung cancer it is over expressed in 43- 89 % of cases.
 [27] 
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The inhibition of EGFR by using tyrosine kinase inhibitors induces 
apotosis and reduces proliferation of neoplastic cells. Thus the EGFR 
inhibitors are new promising targeted therapeutic agents in the treatment of 
lung cancer. Erlotinib and gefitinib are commercially available tyrosine kinase 
inhibitors which competitively inhibits ATP binding site of tyrosine kinase 
domain which arrests EGFR signaling pathway. 
Lynch et al found that lung cancer patients who are having mutation in 
tyrosine kinase domain of EGFR respond to gefitinib where as patients with 
no mutation did not respond to gefitinib.
[28] 
Similar results were demonstrated 
by paez et al also.
[29]
 In both the above studies EGFR mutations were found in 
Exon 18, 19 and 21. The two most common EGFR mutation which accounts 
for > 90% of all EGFR mutations are short inframe deletion of exon 19 and 
point mutation of exon 21, that results in replacement of leucine to arginine at 
codon 858(L858R). Other less common mutation sensitive to TKI are G719 in 
exon 18 and L861 in exon 21. In two retrospective studies deletion 19 
compared to exon 21 mutation had good prognosis. 
The most common method used for EGFR mutation is direct 
sequencing. The main drawback of direct sequencing is low sensitivity and 
increased risk of contamination.
[9]
 The newer and more sensitive method of 
detecting EGFR mutation is reverse transcriptase polymerase chain reaction 
(RT-PCR) using specific probes or amplified refractory mutation system 
(ARMS) technique.
[10,11]
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Because of the cost and time involved in PCR, surrogate markers using 
IHC tests to detect EGFR mutation will make difference in the early detection 
of EGFR mutation which will instead make a difference in management of 
lung cancer especially in countries like India. 
Various IHC markers have been tried which act as surrogate marker to 
EGFR mutation. The important markers are downstream proteins in EGFR 
pathways in the phosphorylated forms like P-AKT, P- EGFR and TTF-1. 
P- AKT is a serine threonine protein kinase which regulates many of 
key mechanism responsible for carcinogenesis like apoptosis, angiogenesis 
and cell cycle propagation.
 [30]
 
In a study by Amit shah et al where he studied 82 lung cancer specimen 
P-AKT protein levels above normal was associated with favorable outcome. In 
multivariate analysis P- AKT was associated with high tumor grade. 
Cytoplasmic positivity and nuclear positivity was present in 96 % and 43 % 
cases respectively. The nuclear positivity of  P-AKT was associated with 
nodal metastasis and poor survival compared to cytoplasimic positivity.
[31]
 
Cappuzo et al evaluated 103 patients in which p-AKT was positive in 
51 patients and  p- AKT in NSCLC is more strongly correlated with female 
gender, absence of smoking history and bronchoalveolar histology and is 
associated with better response rate and overall survival when treated with 
gefitinib.
[32]
  
 
15 
Ikeda S et al studied 130 cases of adenocarcinoma of lung. EGFR 
mutation was detected in 32% of cases and P-AKT by IHC was positive in 
51% of cases, he showed that there is a correlation between p-AKT positivity 
and EGFR mutation especially (L858R mutation) with p=0.040. He also 
suggested that the activation of Akt is dependent on EGFR mutation. 
[33]
 
TTF-1(Thyroid transcription factor 1) is required for development and 
maturation of thyroid and lung. TTF-1 is expressed in type 2 pneumocytes and 
non ciliated bronchial epithelial cells. TTF-1 plays important role in 
sustainment of lung cancer. 
[34]
 
TTF-1 is present in approximately 75% of adenocarcinoma and is 
expressed in only 5% squamous cell carcinoma. Some recent studies have 
shown that TTF-1 is expressed in majority of patients of EGFR mutated lung 
cancer. 
Mary J Fiedler et al evaluated 216 patients of carcinoma lung and found 
EGFR mutation in 11.6% of patients.TTF 1 was positive in 71% 
adenocarcinoma patients. TTF 1 was strongly associated with EGFR mutation 
(p=0.0060).He stated that TTF  is an indirect marker for EGFR mutation and 
patients with positivity of TTF should strictly be screened for EGFR mutation.
 
[35]
 
Julian Vincenta et al from his study, evaluated 810 NSCLC patients 
from 2004 to 2010, demonstrated EGFR mutation in 114 patients (14%). TTF 
1 was positive in 92% patients. He concluded that negative predictive value of 
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TTF-1 was >95 % when correlating to EGFR mutation and also suggested that 
this can be used as surrogate marker and chemotherapy can be started if it is 
urgent in TTF-1 negative patients and in case of TTF-1 positive patients it is 
better to wait for EGFR mutation report.
[36]
 
Sun PL et al evaluated 382 Korean patients with non small cell lung 
cancer. EGFR mutation was positive in 196 patients (51.3%) and EGFR 
mutation was most prevalent in BAC subtype of lung cancer. He also 
demonstrated strong correlation between EGFR mutation and TTF1 positivity 
(p<0.001).
 [37]
 
Somaih et al evaluated 693 adenocarcinoma, in which TTF status was 
known in 301 patients and EGFR mutation was positive in 224 patients. Only 
2 patients out of 224 patients who were EGFR positive had TTF negative. He 
hypothesized that adenocarcinoma of lung that is TTF-1 negative have 99 % 
probability of having EGFR mutation negativity and can be started on 
chemotherapy. 
[38]
 
Indian Data on Outcome of Advanced Carcinoma Lung 
 
Recent retrospective analysis by Rajappa et al from India where he 
analysed 194 patients with stage 3 and 4 NSCLC quoted overall survival was 
ranging from 6.2 to 8.7 months with  cisplatin based doublet chemotherapy. 
One and two year overall survival in this study was 29.8% and 9.7 %. The 
survival was significantly better in subset of patients who were non smokers 
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and in females. He also stated that the survival with first generation platinum 
doublet was similar to second generation platinum doublets.
 [39] 
 
Prevalence of EGFR Mutation in India 
Only limited data is available regarding EGFR mutation status in Indian 
population. The only largest study which has analyzed EGFR mutation status 
from India was published by R Sahoo et al. 
In this  analysis of 220 patients of NSCLC, in which majority was stage 
3 and 4 disease, EGFR mutation was found in as high as 51.6 % of patients. 
The 2 most important mutations found were deletion 19 (52%) followed by 
missence mutation in exon 21 (26%). Mutation 19 and 21 were significantly 
more in non smokers and females. 
[40] 
Louis et al in his paper analyzed 120 patients of stage 3B and 4 NSCLC 
who presented at cancer institute, Chennai. Patients were stared on upfront 
gefitinib based on parameters like female sex, non smoking status, 
adenocarcinoma histology and poor performance status. PFS and OS of the 
population were 5 months and 7.5 months respectively. PFS was significantly 
better with non smokers, female sex and upfront treatment with gefitinib.12 
months PFS of upfront gefitinib verses chemotherapy were 26 % and 16 % 
respectively. Toxicity profile favored gefitinib compared to chemotherapy.
[12]
 
Another publication by Aggarwal et al in which EGFR mutation of 55 
non smokers were analyzed .EGFR mutation was positive in 27 of 49 cases. 
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EGFR mutation was strikingly more common in south Indian patients 
compared to north Indian patients (65 %v/s 33 %).
[41] 
With these limited data is clear evidence that EGFR mutation status and 
stratification of treatment depending on EGFR mutation status is not practiced 
universally and any data addressing the above issue will be encouraging. 
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MATERIALS AND METHODS 
Study Design and Center  
Prospective, observational, single institutional study conducted in 
patients of adenocarcinoma lung, under medical oncology department at 
Adyar Cancer Institute, Chennai. For IHC correlation of EGFR mutation status 
with p-AKT, TTF 1, 28 patients who were diagnosed having adenocarcinoma 
lung at our institute during   2009 -2010 were analyzed retrospectively. 
However they were excluded for survival and quality of life analysis.  
 
Study Duration  
The study was conducted between June 2010 to January 2013 
 
Inclusion criteria 
 Adenocarcinoma of lung by tissue diagnosis 
 ECOG performance status  <= 3 
 Age > 18 years 
 
Exclusion criteria 
 Lung cancers with non adenomatous histology  
 ECOG performance status  4 
 Pregnant and lactating patient 
 Age < 18 years 
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Patients who met eligibility criteria were included in the study. Detailed 
history with special emphasis on smoking history was taken. The patients 
underwent thorough clinical examination, and base line blood investigation 
including haemogram, renal and liver function tests. Patients also underwent 
chest X Ray, CT scan of the chest, ultrasound abdomen and bone scan. PET 
scan was done wherever necessary based on patients symptoms.  
 
EGFR mutation was done by using scorpian probe based ARMS – PCR 
technique  in Triesta Lab, Bangalore from tissue samples, either from  
formalin fixed paraffin embedded tissue(FFPE) or FNAC (fine needle 
aspiration cytology) obtained either from tumour tissues / metastatic nodes or 
from cell blocks from pleural fluid which was positive for malignant cells. 
IHC was done on tumour tissue samples by using thyroid transcription 
factor 1 (TTF 1 ,Leika-product code NCL-TTF-1) and phospho AKT(p-AKT, 
cell signaling technology ,product code#4060P) 
 
After tissue diagnosis and staging investigation, patients having advanced 
carcinoma lung who were EGFR mutation positive either received 
erlotinib/gefitinib and if found to be EGFR mutation negative received 
chemotherapy .The choice of chemotherapy was based on cancer institute 
treatment protocol guidelines. 
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Patients were followed up monthly, where detail history regarding 
improvement / worsening of symptoms were noted with special emphasis on 
chemotherapy related toxicities [toxicity grading was done according to 
National Cancer Institute Common Terminology Criteria for Adverse Events( 
NCI- CTCAE)]
 
.Patients were also examined in detail  for signs of 
progression.
[42] 
 
Patients underwent response evaluation every 3 monthly with CT scan 
chest, ultrasound abdomen. PET scan and bone scan were done wherever 
necessary based on patients symptoms. Complete response (CR), partial 
response (PR) and progressive disease was defined according to response 
evaluation criteria in solid tumor (RECIST) criteria.
 [43] 
 
In case of progressive disease, chemotherapy regimen was changed as per 
cancer institute treatment protocol. In case of significant chemotherapy related 
toxicities (especially grade 3-4 toxicities), either drug dosage was reduced or 
drug regimen was changed according to cancer institute treatment guidelines. 
 
Quality of life (QOL) assessment was done at baseline and at 3 months. 
The QOL questionnaire was filled by patients in the presence of interviewer 
with in prescribed time. 
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Patients were staged according to American joint committee for cancer 
(AJCC) 7
th
 edition  
 
 
 
Current smokers were defined as those who smoked > 100 cigarettes/ 
beedies in their life time and those patients when asked question “currently do 
you smoke every day”, answered “yes” or “some days”.  
 
Nonsmokers were defined as patients who had smoked <100 cigarettes 
in their  lifetime and  former light smokers were defined as those who had 
stopped smoking at least 15 years previously and smoked  a total of ≤10 pack-
years of cigarettes.
 [44] 
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Methodology of EGFR Mutation  
1 DNA Extraction  
Genomic DNA was extracted from different types of clinical materials 
such as FNAC smears, pleural effusion smears and cell blocks, core biopsies 
of lung and SCLN biopsies. The DNA was extracted as per the manufacturer's 
protocol (QIA Amp DNA Minikit).  
 
2 DNA Quantification 
DNA were quantified by using RNAse-P (Part no: 4316831,Applied 
Biosystems) as per the kit insert. 1000 pg of DNA was utilized for each test. 
 
3. Real-time PCR 
Exons 18,19,20 and 21 of the EGFR gene were screened for 
hotspots(oncogenicdriver mutations) using Scorpions ARMS Realtime PCR 
technology and analyzed using DxS ARMS-PCR kit (Product Code: EG-03 
and EG-04). 29 somatic mutations that included the resistance mutation 
T790M were  screened in this assay for all the samples. EGFR mutation was 
considered positive if patients sample was tested positive for 1 of the 29 
mutation. 
 
Methodology of Immunohistochemitry 
Immunohistochemistry was performed on formalin-fixed, paraffin 
embedded sections, FNAC slides or pleural effusion smears and cell blocks. 
Five micrometer paraffin sections on APES coated glass microslides were 
used. 
24 
The following steps were carried out: 
1. Dewaxing and Rehydration: Sections were deparaffinized and rehydrated 
by consecutive submersions in Xylene (twice for 8 mins), absolute ethanol 
(twice for 3 mins) and hydrated in water (5 min). 
2. Blocking of Endogenous Peroxidase action: Endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen peroxide for 10 mins 
at room temperature and slides were washed in Tris Buffer Saline (TBS pH 
7.6). 
3. Antigen retrieval: The sections were then subjected to antigen retrieval in 
Tris EDTA buffer by using pressure cooker . 
4. Incubation with specific primary antibody: After cooling down to room 
temperature, the sections were washed in TBS and incubated with the 
specific antibodies( P- AKT or TTF-1) overnight at room temperature in a 
humid chamber. Following day, the slides were washed with TBS for 5 
mins three times to remove the unbound primary antibody. 
5. Incubation with Labelled Polymer (EnVision+ System-HRP) (DAKO): 
Tissue sections were then incubated at room temperature for 2 hours with 
Labelled Polymer. The slides were then washed with TBS for 5 mins three 
times to remove unbound polymer. 
6. Incubation with substrate-chromogen: The sections were then incubated 
with liquid DAB+Substrate-chromogen for 5-10 mins. 
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7. Counterstaining and mounting: The sections were then counterstained with 
haematoxylin, dehydrated, cleared and mounted using DPX. 
 
Negative control slides were processed under same conditions as above 
omitting the primary antibody. 
 
Quality of Life Assessment 
The QOL was assessed by using standardized CANCER INSTITUTE - 
QUALITY OF LIFE QUESTIONNAIRE (CI-QOL-Q) Version II. 
[45]
 This is a 
modified version of the EORTC –QOL 30 questionnaire and  has 41 questions 
that has been standardized for the Indian population. This mainly assesses the 
quality of life in 11 dimensions. They are  
 General well being 
 Physical well being  
 Psychological well being 
 Interpersonal relationship 
 Sexual and personal ability 
 Cognitive well being 
 Optimism and belief 
 Economical well being 
 Informational support 
 Patient physician relationship 
 Body image. 
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The norms of QOL scale version 2 is as follows: 
 
Score Quality of life 
below 99 very low 
99-117 low 
118-146 average 
147-165 high 
Above 165 Very high 
 
QOL was also assessed by using EORTC-QOQ-C30 (version 3 ) and 
site specific EORTC-QCQ-LC13, which mainly assesses improvement in 
symptomatology in patients suffering from carcinoma lung. 
 
The quality of life was assessed at baseline and was compared to the 
quality of life at 3 months for patients on TKI and chemotherapy. 
 
27 
STATISTICAL ANALYSIS 
 
SPSS version 17.0 (SPSS Inc) was used for statistical analysis. Chi 
square test was used to find out correlation between categorical variables and 
survival. Kaplan Meier survival plot was used for estimating the progression 
free survival (PFS) and Overall survival (OS).Student „T‟ test was used to 
compare mean differences of quantifiable variables. Log rank test was used in 
measurement of independent risk factor affecting PFS and OS in univariate 
analysis and was also used to estimate differences in survival curve. Cox –Ph 
model was employed for measurement of independent risk factor affecting 
PFS and OS in multivariate analysis. Kappa co-efficient was used to assess the 
level of agreement between EGFR mutation by PCR with P-AKT, TTF 1 by 
IHC. 
 
Cofactors investigated in the univariate and multivariate analysis 
included age, gender, performance status, co morbidities, smoking status and 
EGFR mutation status. 
 
QOL assessment was done by using the descriptive statistics, paired 
sample‟t‟ test was used to compare the mean differences in QOL scores. The 
QOL data was also analyzed by using SPSS software version 17. 
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RESULTS 
 
A Total of 101 patients were included in the study, of which 73 patients 
were followed up prospectively. The first case was enrolled on June 2010 and 
last case was enrolled on January 2013. 28 patients of adenocarcinoma lung 
were analyzed retrospectively for IHC correlation between EGFR mutation 
and P- AKT, TTF-1 .These patients were excluded from survival analysis and 
quality of life analysis. 
 
Age Distribution 
The youngest patient in our study was 35 years and oldest being 78 
years. The median age of study population was 55 years .There were 30 
patients below age of 55 years and 43 patients above age of 55 years. The age 
distribution is represented in bar diagram below. 
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Sex Distribution 
Among 73 patients included in the study 22 patients were females and 
51 patients were males. 
51
22
Sex distribution
males females
 
Presenting symptoms 
The presenting symptoms has been shown by the bar diagram below. The 
most common symptom at presentation was cough which was present in 57 
patients. Headache/ focal neurological deficit was present in only 4 patients at 
presentation. 
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Smoking Status 
Among 73 patients enrolled in the study , 31 patients were smokers and 
42 patients were non smokers. The median duration of smoking was 24 pack 
years. 
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Performance Status at Presentation 
Of the 73 patients who were followed up prospectively 36 patients were 
in performance status 1, 28 patients were in performance status 2 and nine 
patients were in performance status 3.  
 
 
Comorbidities 
23  patients out of 73  prospectively studied  patients had co 
morbidities. The various co morbidities were as follows 
 
Co morbidities Number of patients 
Diabetes 9 
Hypertension 6 
Ischemic heart disease 3 
Diabetes and hypertension 3 
Diabetes , hypertension and IHD 2 
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Stage at Presentation 
Among 73 patients who were prospectively studied the stage of 
presentation is as follows 
Stage Number of patients 
1 1 
3a 1 
3b 9 
4 62 
 
Metastatic Pattern at Presentation 
Among the 62 patients who had metastatic disease the pattern of 
metastasis  at presentation is as follows 
Site Number 
Bone 27 
Bilateral  lung nodule/pleural effusion 22 
Brain 6 
Adrenal 8 
Liver 6 
Spleen 1 
Uterus 1 
Bone marrow 1 
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The two most common site of metastasis were bone, bilateral lung 
nodule/ pleural effusion accounting for 43.5% and 35.4% of metastasis 
respectively. 
 
Tissue Diagnosis  
Tissue diagnosis in our study population was obtained as follows: 
  
Procedure Number 
Bronchoscopic  biopsy 4 
Bone marrow biopsy 1 
FNAC  of lung lesion/SCL node 6 
Surgery of primary lesion 2 
Pleural fluid cytology 3 
SCL node biopsy 8 
CT guided trucut biopsy 49 
 
EGFR Mutation Status in Prospectively Studied Samples 
Among the 73 prospectively studied patients EGFR mutation status is 
as follows. EGFR  mutation was positive in 34 patients (48.2%), negative in 
36 patients(51.6%) and sample was inadequate in 3 patients. 13 out of 22 
females(59%) and 21 out of 51 males(41%) were EGFR mutation positive. 
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Types  of EGFR  Mutation 
Among the 34 EGFR positive patients, mutation pattern is as follows: 
Mutations Number 
Deletion ( Exon 19) 23 
L858R(Exon 21) 9 
G719X(Exon 18) 1 
L858R(Exon 21)+ G719X(Exon 18) 1 
 
Chemotherapeutic Regimens  
Among 73 patients one patient who was a case of stage 1 lung cancer 
after surgery was kept under follow up, one patient expired before starting the 
chemotherapy and one patient lost follow up before starting chemotherapy. 
Among the 70 patients the various chemotherapeutic agents received at 
presentation is as follows: 
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Chemotherapeutic regimen numbers 
Pemetrexed + carboplatin/cisplatin 22 
Gemcitabine+carboplatin 7 
Etoposide+ cisplatin 4 
Oral etoposide 2 
Paclitaxel+ carboplatin 1 
Gefitinib 23 
Erlotinib 11 
 
Toxicity profile of Tyrosine kinase inhibitors 
Toxicity profile of TKI‟s were as follows 
Toxicity Number 
Diarrhoea 4 
Skin rash 16 
Interstitial fibrosis/ILD 1 
Mucositis 2 
Increased SGOT/SGPT(>5 times ULN) 3 
Hand foot syndrome 2 
Conjunctivitis 1 
 
Among the four patients who had diarrhoea, three had grade 2 
diarrhoea and one had grade 3 diarrhoea and all were managed conservatively. 
The TKI was continued in all 4 patients under close observation. 
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The major side effect of TKI was skin rash. Among the 16 patients who 
developed skin rash, three patients had grade 1, five patients had grade 2, six 
patients had grade 3, two patients had grade 4 skin rash. Both patients who 
developed grade 4 skin rash were on erlotinib. 
Skin rash was the major problem in patients who were started on 
erlotinib . Among 11 patients who were started on erlotinib , nine developed 
skin rash. Seven patients among 22 patients who were started on gefitinib 
developed skin toxicity. Erlotinib dose was reduced from 150mg to 100 mg in 
four patients, and in four   patients erlotinib was changed to gefitinib. Gefitinib 
induced rash was managed conservatively and the drug was continued in all 
the patients once rash subsided. 
One patient had gefitinib induced interstitial lung disease and the drug 
was discontinued. One patient on gefitinib had conjunctivitis which was 
managed with temporary stopping of drug and topical steroid drops. Gefitinib 
was restarted once conjunctivitis subsided under close observation. 
 
* Picture showing erlotinib induced rash on the back 
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Toxicity Profile in Chemotherapy Arm 
The major toxicities in chemotherapy arm are as follows 
Toxicities numbers 
Fatigue 12 
Vomiting(> grade 2) 5 
Neurtopenia (>grade 2) 13 
Thrombocytopenia (> grade 2) 5 
Peripheral neuropathy 1 
Mucositis 2 
Diarrhoea(> grade 2) 2 
 
The most common side effect in chemotherapy arm was neutropenia 
and fatigue. Fatigue was most commonly observed in patients receiving 
pemetrexed chemotherapy. Among 12 patients who had fatigue, 10 had grade 
2 fatigue and two had grade 3 fatigue. Among 13 patients who had 
neutropenia, eight had grade 2 neutropenia, three  had grade 3 neutropenia and 
two had grade 4 neutropenia. 
There was no treatment related mortality in both TKI and 
chemotherapy arm. 
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Survival analysis 
70 patients were eligible for all the survival analysis. The one year 
progression free survival and overall survival of whole study population was 
51.1% and 72.6%. 
The median duration of follow up in chemotherapy group was 6 months 
and that with TKI group was 8 months. The PFS was more in TKI arm as 
compared to chemotherapy arm, that is 7.8 months v/s  6.28  months but this  
was not statistically significant(p= 0.22). One year PFS in TKI group 
compared to chemotherapy group was 61.2 %v/s 42.4% with p=0.37 which 
again was not statistically significant. 
 
 
 
39 
The one year overall survival in patients with TKI was 80.7%  v/s 
55.9% in patients on chemotherapy, with p=0.08 which again was not 
statistically significant. 
 
 
There was no difference in survival between patient with 2 most 
commonly found mutations, that is del exon 19 and L858R in exon 21. 
 
Correlation between Age and Survival 
One year overall survival in patients > 55 years and those patients with 
age < 55 years was 66.1 % v/s 82.9% which was statistically not significant 
(p=0.61) 
 
Correlation  between  Smoking and Survival 
The one year overall survival of smokers was 32.3% compared  to 
94.4% in non smokers which was statistically significant (p= 0.001) 
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Correlation between Smoking, EGFR Mutation and Survival 
       ONE YEAR OVERALL SURVIVAL 
 EGFR +VE EGFR - VE 
SMOKERS 53.3%(6) 33.5%(23) 
NON SMOKERS 95.5%(28) 92.3%(13) 
 
*figures inside brackets indicate number of patients 
 
Patients who were non smokers and who were EGFR positive had 
highest survival.  Smoking emerged as strongest factor for survival after 
adjusting for EGFR mutation status. Smokers had 5 fold increased risk of 
dying compared to non smokers. 
 
Correlation  of Sex and Survival 
Females had 1 year survival of 90.2 % and males had 1 year survival of 
61.7% which was not statistically significant (p=0.08) 
 
Correlation between Sex, EGFR Status and Overall Survival 
ONE YEAR OVERALL SURVIVAL 
 EGFR -VE EGFR +VE 
MEN 49.2% (27) 81.6% (21) 
WOMEN 74.1% (19) 100%(13) 
 
*figures inside brackets indicate number of patients 
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Thirteen women who were EGFR positive had 1 year survival of 100% 
after starting TKI, the worst outcome was with men who were EGFR negative 
(49.2%). 
Correlation between Co morbidities and Survival 
Patients without co morbidities had 1 year survival of 82.2% and those 
with co morbidities had survival of 52.8%. This was not statistically 
significant (p=0.17). 
Correlation between Performance Status and Survival 
Survival according to performance status is shown below 
Performance status Overall survival(n) 
PS-1 92.8%(35) 
PS-2 59.2%(28) 
PS-3 0(7) 
 
Survival difference between patients in PS1 and PS2 was statically 
significant (p=0.006) .Among the patients who presented in PS 2 the 1 year 
overall  survival with TKI and chemotherapy was 75.8% v/s 49.5 % which 
was statistically significant (p=0.006). 
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Summary of Univariate Analysis. 
Factor at baseline Subgroups 
No. of 
patients 
1 year 
Survival 
p value 
Age <55 years 29 82.8% 0.61 
>55 years 41 66.1% 
Sex Male 48 61.7% 0.08 
Female 22 90.2% 
Smoking Positive 29 32.3% 0.001 
Negative 41 94.4% 
Comorbidities Yes 21 52.8% 0.17 
No 49 82.2% 
Performance 
status 
PS 1 35 91.8 
 
 
0.006 PS 2 28 59.2 
PS 3 7 0 
EGFR mutation Yes 34 89.7% 0.08 
No 36 55.9% 
Types of EGFR 
mutation 
Deletion ( exon 19) 23 95% 0.441 
L858R(exon 21) 9 80% 
 
43 
In univariate analysis smoking history and performance status were the 
only factors which significantly affected overall survival. 
 
Even in multivariate analysis (Cox regression model), smoking and 
performance status emerged as strongest predictors of outcome. 
 
 
Correlation between EGFR Mutation Status and P-AKT by IHC 
 
Total of 85 patients out of 101 patients were eligible for analysis. 16 
patients were not eligible for analysis due to inadequate tissue sample to do 
IHC/EGFR mutation through PCR. 
 
EGFR mutation was positive in 34 out of the above 85 patients,  
P- AKT was positive in 51 out of above 85 (60%). 
 
 EGFR  +ve EGFR -ve Total P value 
p-AKT +ve 29(85.3%) 21(42%) 50 <0.0001 
p-AKT -ve 5(14.7%) 30(58%) 35 
Total 34 51  
 
The sensitivity and specificity of P-AKT by IHC compared to EGFR 
mutation done through RT-PCR was 85.3% and 58.8% respectively. The 
positive predictive value and negative predictive value of the test was 58% and 
85.5% respectively. The kappa co-efficient for P- AKT was 0.409, which is a 
measure of agreement (>0.5 is taken as significant) 
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IHC X 40.  Tumor cells showing  membrane and cytoplamic positivity to  P- AKT. 
 
Correlation between EGFR Mutation Status and TTF-1 
TTF-1 was positive in 68 of the 85 eligible patients (80%) and was 
negative in rest of the 17 patients (20%). 
 EGFR  +ve EGFR -ve Total P VALUE 
TTF-1 +ve 33(97.1%) 35(68.6%) 68 <0.00001 
TTF-1 -VE 1(2.9%) 16(31.4%) 17 
Total 34 51  
 
The sensitivity and specificity of the test was 97.1% and 31.4% 
respectively. The positive predictive value and negative predictive value of the 
test was 48.5% and 94.1% respectively. The kappa co-efficient was 0.224. 
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IHC X40 :   Tumor cells showing  nuclear  positivity to TTF-1. 
 
Correlation between P-AKT, TTF-1 and EGFR mutation 
 
 EGFR  +ve EGFR -ve Total P value 
TTF +ve and 
P-AKT -ve 
3(11.1%) 13(54.2%) 16 0.002 
TTF +ve and 
P-AKT +ve 
24(88.9%) 11(55.8%) 35 
Total 27 24  
 
In correlation study of  p-AKT with EGFR mutation status  and TTF-1 
with EGFR mutation status, even though  negative predictive value was very 
high, the positive predictive value was very low and they had  high incidence 
of false positivity.  
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In correlation of  EGFR mutation status with  subset of patients having 
TTF-1 positive and P-AKT positive compared to   TTF-1 positive and P-AKT  
negative had sensitivity and specificity of 88.9% and 54.2 % respectively and 
had positive predictive value of 68.6%  and negative predictive value of 
90%.The false positivity was  as low as 31.4%. Kappa co-efficient was 0.439. 
The positive predictive value was significantly higher and false positivity was 
much lesser compared to TTF- 1 and P-AKT assessed seperately with EGFR 
mutation status. 
 
Correlation of P-AKT and Survival 
Patients who were P- AKT positive had one year overall survival of 
76.4% compared to patients who were p-AKT negative who had overall 
survival of 61.7% which was statistically not significant (p=0.79).Among 
those who had P-AKT positivity, patients who were started on TKI had better 
outcome than those started on chemotherapy (88.2% to 65%), even though this 
was statistically not significant (p=0.214). 
QOL Assessment 
 
43 patients of 73 patients completed both base line and 2
nd
 assessment 
which was 3 months after starting the treatment. The CI-QOL scores are as 
follows  
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CI –QOL-Q scoring at base line  CI –QOL-Q scoring at 
2
nd
  assessment 
 
Score Frequency Percent  Frequency Percent 
Very low 2 4.7%  5 11.6% 
Low 11 25.5%  8 18.6% 
Average 24 55.8%  22 51.2% 
High 6 14.0%  5 11.6% 
Very high 0 0  3 7% 
Total 43 100%  43 100% 
[ 
The mean average score at base line was 128 and that at 2
nd
   
assessment was 126, which indicates that the lung cancer in our study had 
average quality of life. 
Among the 43 patients,20 patients were on TKI and the remaining 23 
were on chemotherapy. The comparison between TKI arm and chemotherapy 
arm between baseline and 2
nd 
assessment is as follows 
 
  MEAN SD P Value 
CI-QOL Q  
ASSESSMENT1 
TKI 128 21.78 0.931 
CHEMO 128.52 17.4 
CI-QOL Q  
ASSESSMENT2 
TKI 132.83 25.51 0.126 
CHEMO 122.24 18.98 
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The mean score in patients on TKI and chemotherapy was same at base 
line , but during  2
nd
  assessment TKI patients had better quality of life 
compared to patients on chemotherapy, but this improvement was not 
statistically significant(p=0.126). 
 
The mean EORTC C30 score in TKI group and chemotherapy group at 
baseline  assessment was 56.28 v/s 57.56 , and same during 2
nd
 
  
assessment 
was 57.22 v/s 60.12 , none of these were statistically significant. 
 
There was a statistical improvement in global health scale (which deals 
with overall health and overall QOL in the past 1 week) between TKI group 
and chemotherapy group during second assessment. 
 
  MEAN SD P Value 
GHS 
ASSESSMENT1 
TKI 6.28 1.23 0.277 
CHEMO 6.78 1.23 
GHS 
ASSESSMENT2 
TKI 10.24 3.03 0.031 
CHEMO 8.38 2.30 
 
 
There was no statistical difference between TKI arm and chemotherapy 
arm in site specific EORTC-QCQ-LC13 questionnaire, which focuses with 
improvement in symptomatology of patients with lung cancer. 
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DISCUSSION 
Lung cancer is one of the commonest cancers worldwide and is the 
leading cause of death among both males and females throughout the world. 
Around 85 % lung cancer present in advanced stage, and the overall survival 
of metastatic lung cancer has been dismal. 
The discovery of tyrosine kinase inhibitors, has added new dimension 
in the treatment of EGFR mutated advanced carcinoma lung, improving PFS 
and OS of patients with EGFR mutation. 
The incidence of EGFR mutation is thought to be 15% in western 
population and around 50 % in Asian population. 
[8, 22, 23] 
The major problem in 
EGFR mutation testing is the technique used in testing. The DNA sequencing 
method which was being used commonly has been replaced by newer 
technique because of low sensitivity and contamination problems. 
[9]
 
The most common method which is used extensively in recent times for 
EGFR mutation testing is ARMS- PCR technique. But this test is very 
expensive and takes 7- 10 days for the results to be available. Hence in 
patients who need treatment immediately, waiting for EGFR report will delay 
the treatment. 
In Indian scenario any surrogate tests for EGFR mutation which is cost 
effective, highly sensitive and less time consuming will be very useful. 
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This study was carried out to find out answers for following questions 
 Data regarding EGFR mutation status in Indian population is limited. This 
study is designed to detect EGFR mutation status by using ARMS- PCR 
method, also to assess the response to treatment which was   started as per 
EGFR mutation status. 
 In this study we tried to know whether any correlation exists between 
EGFR mutation detected through ARMS-PCR method and   P-AKT and 
TTF-1 which was performed through IHC method, which is less expensive 
and less time consuming. 
 We also tried to compare quality of life in patients treated with 
chemotherapy and EGFR inhibitors by using questionnaire standardized to 
Indian patients. 
In our study, the median age of presentation was 55 years which is a 
decade younger to those patients presented in EURTAC study, which was 
carried out in European population but is comparable with median age of 
presentation of IPASS study and OPTIMAL study which was carried out on 
Asian population.
 [8, 22, 23]
 
In our study, 70 % patients were males and only 30 % were females which 
may be probably due to decreased smoking habit among females. 31 out of 
73(42.4%) patients included in the study were smokers which is higher than 
that quoted in EURTAC and OPTIMAL study (35% and 41.8%  
respectively).
 [22, 23]
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Most of the patients in our study presented in good performance status and 
around 50% of patients presented in PS-1.The most common symptom at 
presentation in our study was cough.  
 
Around 84% of all patients included in the study were having metastatic 
disease and most common site of metastasis was either bone or lung (pleural 
effusion or bilateral lung nodule). This figure is comparable with that quoted 
by Sahn HA et al. 
[46]   
 
Brain metastasis was present in six out of 62 patients with metastatic 
disease, accounting for 9.6% of all metastasis. Sen et al has quoted that 25 % 
metastatic lung cancer presents with brain metastasis. 
[47] 
 
Prevalence of EGFR mutation in our study population was 48.2%. In 
IPASS study which was done from East Asia, where only selected population 
of non smokers with adenocarcioma lung were included ,the EGFR mutation 
was present in 59.7% patients. In a study conducted by Sahoo R et al, in 
Indian patients, EGFR mutation was present in 51.8% of patients. 
[8,39] 
 
The most common mutations found in our study were deletion in exon 19 
and mutation at exon 21(L858R). Together these two mutations accounted for 
94% of total EGFR mutation. Above 2 mutations were the predominant 
mutations in IPASS study and study by Sahoo R et al accounting for 96% and 
78% of the mutations respectively.
 [8, 40] 
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Among 34 EGFR mutation positive patients, 23 patients received gefitinib 
and 11 patients received erlotinib. Among these 34 patients, four patients were 
started initially on chemotherapy and were changed subsequently after 1
st
 
cycle of chemotherapy   to TKI once EGFR reports were available. 
 
Among 36 patients who were EGFR negative, 22 patients received 
pemetrexed+carboplatin/cisplatin. Other chemotherapy which were 
administered were gemcitabine/carboplatin, etoposide/cisplatin, oral etoposide 
and paclitaxel/carboplatin. Three   EGFR negative patients who were initially 
started on TKI were subsequently changed to chemotherapy once EGFR 
results were available. 
 
The major toxicity with TKI‟S was skin rash which was present in 47 % of 
patients. All patients were treated with topical clindamycine cream and 
antihistaminics. 
 
In our study grade 3 or 4 skin rash was present in eight patients (23.5%) 
which is much more than that quoted in IPASS and OPTIMAL study (3.1 % 
and 2 % respectively).
 [8, 22]
  
 
We also noticed that erlotinib was  largely responsible for skin toxicity 
in TKI group. Nine of the total 11  patients who received erlotinib developed 
skin toxicity. Two patients who developed grade 4 skin toxicity in our study 
were on erlotinib.  Four patients were managed by reducing the dose of 
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erlotinib from 150 mg to 100 mg and the other four patients required change 
of treatment to gefitinib. This toxicity due to erlotinib resulted in significant 
treatment interruptions. 
 
All the patients who developed skin toxicity with gefitinib were 
managed with topical clindamycine ointment and antihistaminics and were 
restarted on the drug once rash subsided. The treatment interruption due to 
gefitinib induced skin toxicity was negligible. 
 
The differential toxicity due to gefitinib and erlotinib may be because 
erlotinib is prescribed at a dose close to its maximal tolerable dose(MTD) 
where as gefitinib is prescribed at a dose much lesser than  MTD. 
 
Diarrhoea was observed in only four patients treated with TKI‟S 
(29.4%) which is less than that observed in IPASS study (46.6%) .  
 
The major toxicities with chemotherapy were fatigue and 
haemotological toxicity,mainly neutropenia. Fatigue was mostly observed in 
patients receiving pemetrexed chemotherapy. Fatigue was the main side effect 
in patients receiving pemetrexed / cisplatin chemotherapy in LUX LUNG 3 
trial which was observed in 46.2 % patients. 
[48] 
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The one year progression free survival and overall survival of whole 
study population was 51.1% and 72.6% respectively. One year overall survival 
for carcinoma lung (including all stages), enrolled in year 2002-2003  from 
hospital based cancer registries in Chennai , was 51.8%.
[49]
In the study 
conducted by Rajappa et al the one year overall survival of advanced lung 
cancer in Indian patients was 29.2% with cisplatin based doublet 
chemotherapy which is much less than that observed in our study indicating 
that treatment based on EGFR mutation status  has significantly increased 
survival.
[39] 
 
The PFS in TKI group was 7.8 months compared to 6.28 months in 
chemotherapy group. Even though this was not statistically significant it is 
clear from our study that EGFR positive patients who were started on upfront 
TKI has improved PFS compared to EGFR negative patients started on  
standard chemotherapy. One year PFS in TKI group was 61.2 % compared to 
42.4% of chemotherapy group which again was not statistically significant. 
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The various studies showing PFS of TKI compared to chemotherapy 
are: 
Study Chemotherapy TKI Significance 
IPASS study(no 
randomization based on 
EGFR status ).
[8]
 
5.6 months 5.7 months Not significant 
But in EGFR mutated pts 
chemotherapy  TKI had better 
PFS compared to 
chemotherapy 
Significant with  
HR of 0.74 
OPTIMAX (in EGFR 
mutated pts).
[21]
 
4.6 months 12.1 months Significant 
P=0.0001 
LUX-LUNG 3 (in EGFR 
mutated pt).
[47]
 
6.9 months 11.1 months   Significant 
P=0.0001 
EURTAC trial(EGFR 
mutated pts).
[22]
 
5.2 months 9.7 months Significant 
P=0.0001 
Robert A. Louis.
[40]
 5months 7 months Significant 
P=0.024 
Our study 6.28 months 7.8 months Not significant 
P=0.14 
 
One year overall survival was better in TKI arm compared to 
chemotherapy arm (80.7% v/s 55.9 %) even though it was not statistically 
significant. Longer follow up is required for accurate calculation of overall 
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survival.  In the study by Louis et al, conducted at our institute, one year OS 
with chemotherapy arm was 40.4 % compared to 44.4 % in TKI arm.
 [12] 
 
In univariate analysis and multivariate analysis various  factors 
influencing overall survival  of carcinoma lung  like age, sex, smoking status, 
EGFR mutation status, type of EGFR mutation, comorbidities and 
performance status at presentation were analyzed. Both in univariate and 
multivariate analysis, only smoking status and performance status at 
presentation emerged as independent risk factors which influence overall 
survival. 
 
In IPASS trial only age had emerged as independent risk factor for 
survival in univariate analysis. None of the other factors influenced survival. 
In the study by Louis et al female sex, non smokers and upfront treatment with 
gefitinib had impact on  PFS in univariate analysis but in multivariate analysis 
none of the factors emerged significant
  [8, 12]
 
 
A subset of patients who were 1) non smokers and EGFR positive 2) 
females who are  EGFR positive started on TKI had the best survival outcome 
in our study. None of the 13 females who were EGFR positive died within one 
year accounting to 100% one year overall survival in this subset. 
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Smoking when adjusted for EGFR mutation status emerged as strongest 
risk factor for survival, that is smokers even though EGFR positive after 
starting on TKI had inferior survival compared to patients who were non 
smokers, EGFR negative and who were started on chemotherapy (53.3% v/s 
92.3%).In our study smokers had 5 fold more risk of dying compared to non 
smokers. 
 
In our study P-AKT by IHC was positive in 68% of the cases. There 
was a correlation between P- AKT and EGFR mutation with p value of 
<0.0001.The sensitivity and specificity of the test was 85.5% and 58.8% 
respectively. Only five out of 34 EGFR positive patients were P- AKT 
negative resulting negative predictive value of 85.5%. There was a trend 
towards  agreement between EGFR mutation status and P- AKT, with kappa 
value of 0.409. 
 
But for a test to become a strong surrogate method so as to replace the 
existing gold standard method, should have high sensitivity and specificity.  In 
our study p- AKT has specificity of 58.8% and false positive rate of 42 %. 
Hence even though there is strong correlation between EGFR mutation status 
and P- AKT, it cannot replace the RT- PCR technique in detection of EGFR 
mutation status. 
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In study by Ikeda et al, p- AKT by IHC was positive in 51% cases and 
correlation between EGFR mutation and p- AKT was significant with 
p=0.002. In this study also, there was a high number of false positivity with P-
AKT. 
 
In our study, patients who were P- AKT positive had 1 year overall 
survival of 76.4% compared to 61.7% in patients with p- AKT negative and 
this was not statistically significant (p=0.79). In patients who were P-AKT 
positive when treated with TKI compared to chemotherapy had better overall 
survival (88.2% v/s 65%) which was again not statistically significant .This 
was contrast to study of Capuzzo et al, where p-AKT positive patients when 
treated with gefitinib had better response rate ,time to progression compared to 
P- AKT negative patients.
[32]
 
 
In our study TTF -1 was positive in 80% of cases, there was statistically 
significant correlation between EGFR mutation positivity and TTF-1 positivity 
(p=<0.0001).The sensitivity and specificity of the test was 97.1% and 31.4% 
respectively. Only one out of 17 TTF-1 negative patients was EGFR mutation 
positive, accounting for negative predictive value of 94.1%. The kappa co-
efficient was 0.224. This sensitivity and negative predictive value is consistent 
with study of Vincent et al and   Sommiah et al who quoted negative 
predictive value of    TTF-1 to  be > 95%.
 [36, 38] 
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P- AKT and TTF-1 has high negative predictive value, which means 
chance of having EGFR mutation positive in patients who are p- AKT, TTF-1 
negative is very less. In patients where P-AKT and TTF-1 negative, EGFR 
mutation testing can be avoided and started on chemotherapy when there is 
urgency in starting treatment. 
 
The problem of false positivity and low sensitivity with TTF-1 and P-
AKT can be partly overcome by testing for above two IHC simultaneously. In 
patients having TTF-1 positive and P-AKT positive, when compared to TTF-1 
positive and P-AKT  negative had sensitivity and specificity of 88.9% and 
54.2 % in detecting EGFR mutation .The  positive predictive value of 68.6%  
.False positivity was 31.4% which is much lesser compared to P-AKT and  
TTF-1 when they were tested separately. 
 
Improvement in quality of life should be one of the important aims in 
the treatment of metastatic lung cancer, where survival is lesser than one year. 
Therapeutic interventions which improve the quality of life like general well 
being, physical well being and psychological well being should be strongly 
encouraged in the treatment of metastatic carcinoma lung. 
 
There is limited data from India where quality of life has been 
measured using questionnaire standardized for Indian patients. In this study 
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we used cancer institute QOL questionnaire which has been standardized for 
Indian patients. 
[45] 
 
At presentation our study population had average QOL with score of 
128. After treatment patients who were EGFR positive and started on TKI had 
better QOL compared to patients who were EGFR negative and started on 
chemotherapy (mean QOL score of 122.22 v/s 132.83)  even though it was 
statistically non significant. In our study there was significant improvement in 
global health scale during first assessment in TKI arm compared to 
chemotherapy arm (mean of 10.24 v/s 8.38, p=0.031). Our results clearly show 
that patients who are started on TKI upfront had better quality of life 
compared to those started on chemotherapy. 
 
Similar to our study, in OPTIMAL trial which assessed quality of life 
by using  FACT-L, TOI , LCS questionnaire had significant improvement in 
QOL with TKI compared to chemotherapy arm. In IPASS study health related 
quality of life was better in TKI arm in patients who were EGFR positive, and 
in chemotherapy arm in patients who are EGFR negative. 
[50,51]
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CONCLUSIONS 
 Present study is the first prospective study of lung cancer from India, 
where in , treatment decision was  made on EGFR mutation status and 
treatment outcomes were assessed. 
 
 EGFR mutation status in our population was 48.2%. 
 
 The one year PFS and OS of study population was 51.1% and 72.6% 
respectively. 
 
 The high PFS and OS in our study, strongly support the need for EGFR 
mutation testing in all patients of advanced carcinoma lung and importance 
of starting treatment depending on EGFR mutation status. 
 
 Patients who were EGFR mutation positive and started on TKI‟s in the 
upfront setting had better PFS, OS compared to patients who were EGFR 
mutation negative and started on standard chemotherapy. 
 
 Female patients who were EGFR mutation positive had 100% one year  
 
 overall survival with TKI treatment indicating a clinically favorable subset.  
 
 Factors significantly affecting overall survival of carcinoma lung were 
smoking status and performance status at presentation. 
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 The major toxicity with TKI‟s in our study was skin toxicity and the 
incidence of skin toxicity was more with erlotinib compared to gefitinib. 
 
 P- AKT and TTF-1 by IHC has strong correlation with EGFR mutation 
status which was performed through ARMS- RT PCT. But due to low 
specificity and high false positivity these IHC‟s cannot replace RT- PCR 
method in detection of EGFR mutation status. The false positivity can be 
partly reduced by using P-AKT and TTF-1 simultaneously, where in 
patients who are positive for both P-AKT and TTF-1 had lower false 
positivity in detecting EGFR mutation. 
 
 Due to high negative predictive value of P-AKT and TTF-1, in patients 
who are negative for these IHC studies, EGFR mutation testing can be 
avoided and patients can be started on chemotherapy if there is urgency in 
starting the treatment. 
 
 The QOL was assessed by using cancer institute- quality of life 
questionnaire which is standardized for our population. The QOL was 
better with TKI treatment compared to other chemotherapy. 
 
The limitation of our study is the small sample size, short duration of follow 
up and different regimens of chemotherapy used in chemotherapy arm. 
i 
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Proforma 
 
NAME     AGE    SEX 
 
UHID  
 
CONTACT NO  ADDRESS 
 
OCCUPATION  SMOKING  EXP TO CARCINOGEN 
 
SYMPTOMS  DURATION   PS 
1 
2 
3 
 
TISSUE DIAGNOSIS- 
 
SUBTYPE 
 
FINAL DIAGNOSIS 
 
EGFR MUTATION STATUS   TYPE OF SAMPLE SENT 
 
IHC-   EGFR receptor 
            p- AKT     
x 
TREATMENT  GIVEN 
1 . TKI   A)ERLOTINIB  DOSE b)GEFTINIB  DOSE 
2.I V CHEMOTHERAPY  - 
 
SIDE EFFECT OF  TKI 
 
QOL 
 
1
st
 follow up( AFTER  3  MONTH) 
PS  
CHEST X RAY 
CT CHEST 
OTHERS 
 1  CR   2 PR   3 SD  4 Pr D 
 
CHANGE IN TREATMENT     REASON 
DOSE INTURRUPTION       CAUSE 
 
SIDE EFFECT OF  TKI 
2
st
 follow up( AFTER  6 MONTH) 
PS  
CHEST X RAY 
CT CHEST 
 1  CR   2 PR   3 SD  4 Pr D 
xi 
CHANGE IN TREATMENT     REASON 
DOSE INTURRUPTION       CAUSE 
SIDE EFFECT OF  TKI 
 
 
3
rdt
 follow up( AFTER  9 MONTH) 
PS  
CHEST X RAY 
CT CHEST 
 1  CR   2 PR   3 SD   4 Pr D 
CHANGE IN TREATMENT     REASON 
DOSE INTURRUPTION       CAUSE 
SIDE EFFECT OF  TKI 
 
QOL 
 
